Results of Novel Clinical Study of Guselkumab and Golimumab Combination Therapy Show Adults with Moderately to Severely Active Ulcerative Colitis Maintained Higher Rates of Clinical, Histologic, and Endoscopic Remission at Week 38
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from an ongoing analysis of a Phase 2a clinical trial showing adults with moderately to severely active ulcerative colitis (UC) who received 12 weeks of combination induction therapy with guselkumab and golimumab, followed by a transition to guselkumab alone for maintenance, achieved a clinical remission ratea (based on the modified Mayo score [mMayo])b at week 38 of 47.9 percent, a higher rate than induction and maintenance treatment with either guselkumab alone (31.0 percent) or golimumab al...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
No Rise in Guillain-Barre Syndrome Cases After COVID Shots: Study
WEDNESDAY, Oct. 5, 2022 -- A new study has found no evidence that COVID-19 shots increase the incidence of Guillain-Barr é syndrome, according to researchers. " This is important because we can say that there is no significant increased risk of... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 5, 2022 Category: General Medicine Source Type: news
Flu Vaccine Not Linked to Increased Guillain-Barr é Syndrome Risk Flu Vaccine Not Linked to Increased Guillain-Barr é Syndrome Risk
Although past studies have suggested a link between the influenza vaccine and Guillain-Barr é syndrome, a large new study showed no increased risk for older adults ― including those with comorbidities.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - September 27, 2022 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
South Africa: Sahpra Confirms Second Death Linked to J&J Covid-19 Vaccine
[SAnews.gov.za] South Africa has recorded its second fatal case of Guillain-Barre syndrome (GBS) following vaccination with the Johnson & Johnson (J&J) COVID-19 jab, the South African Health Products Regulatory Authority (SAHPRA) announced on Monday. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 13, 2022 Category: African Health Source Type: news
Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
B.C. man among first Canadians approved for COVID-19 vaccine injury payout
Ross Wightman, who was diagnosed with Guillain-Barré Syndrome last year following a dose of the AstraZeneca COVID-19 vaccine, has been approved for a pain and suffering payout under Canada's Vaccine Injury Support Program. (Source: CBC | Health)
Source: CBC | Health - June 1, 2022 Category: Consumer Health News Tags: News/Canada/British Columbia Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
Acute nitrous oxide-induced neuropathy mimicking Guillain-Barr é Syndrome - Qin X, Kang L, Liu X, Jin J, Hu F, Lu W, Deng Y, Chen QY, Dang J.
BACKGROUND AND OBJECTIVE: The early clinical features of nitrous oxide (N(2) O)-induced neuropathy were mimicking that of Guillain-Barr é Syndrome (GBS). We aimed to explore clinical and laboratory characteristics of N(2) O-induced neuropathy in comparison... (Source: SafetyLit)
Source: SafetyLit - May 28, 2022 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Regulatory approval of COVID-19 Vaccine Janssen, MHRA (updated 12th May 2022)
Information for healthcare professionals and the public about the COVID-19 Vaccine Janssen
12 May 2022Updated SPC and PIL: SPC - Under " Special Warnings " section, " Guillain-Barr é syndrome " section updated to include transverse myelitis. PIL - Added info on Neurological disorders - Inflamation of the spinal corrd (transverse myelitis) PIL - Added inflamation of the spinal cord to " Possible side effects " section, under " unknown " heading.
14 February 2022Updated product information for HTML links to Summary of product characteristics and patient information leaflet. The changes are also included in the PDF att...
Source: Current Awareness Service for Health (CASH) - May 12, 2022 Category: Consumer Health News Source Type: news
Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
NEW BRUNSWICK, NJ, May 5, 2022 - Our number one priority is the safety and well-being of those who use the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson, in close coordination with the U.S. Food and Drug Administration (FDA), has updated its U.S. COVID-19 Vaccine Fact Sheet to increase awareness about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition. Language about the risk of TTS has been added to the first page of the Fact Sheet to increase its prominence. Following the update to the Fact Sheet, the Johnson & Johnson COVID-19 vaccine is now...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Source Type: news
New Data Confirm Risk of Guillain-Barre With J & J COVID Shot New Data Confirm Risk of Guillain-Barre With J & J COVID Shot
The data support current US guidance that preferentially recommends use of an mRNA COVID-19 vaccine for primary and booster doses.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - May 3, 2022 Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news
Guillain-barre/Miller Fisher Overlap Syndrome After COVID-19 Guillain-barre/Miller Fisher Overlap Syndrome After COVID-19
An acute motor sensory axonal neuropathy is a neurological complication that may result from COVID-19-provoked Guillain-barre syndrome, as seen in this patient.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 28, 2022 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
Guillain-Barre Risk After COVID-19 Vaccines Low, Surveillance Data Show
(MedPage Today) -- Risk of Guillain-Barré syndrome after COVID-19 vaccines was low overall, but unusually high after the Johnson & Johnson shot, surveillance data showed.
Among 15.1 million doses of COVID-19 vaccines included in the Vaccine... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - April 27, 2022 Category: Infectious Diseases Source Type: news
Risk for Guillain-Barr é Syndrome Up After Ad.26.COV2.S Vaccination
TUESDAY, April 26, 2022 -- The incidence of Guillain-Barré syndrome (GBS) is increased after Ad.26.COV2.S vaccination, but incidence is not increased after mRNA vaccination, according to a study published online April 26 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2022 Category: Pharmaceuticals Source Type: news
Study: Guillain –Barré syndrome risk with COVID-19 vaccines low, but higher with J & J shot
The risk for developing Guillain-Barr é syndrome, a condition that causes severe muscle weakness, after receipt of a COVID-19 vaccine is small, but higher with the Johnson& Johnson shot, according to a study. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 26, 2022 Category: Consumer Health News Source Type: news
